A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
diagnosis of systemic AL amyloidosis;
treatment-naïve;
age ≥18 years;
ability to understand and willingness to sign an informed consent;
non-AL amyloidosis;
previous treatment for AL amyloidosis.
400 patients with AL amyloidosis will be enrolled at diagnosis and evaluated at any of the participating clinical centers.
Cohort
Prospective
Not listed
Mortality at 24 months by stage
Mortality at 24 months by stage will be evaluated
Rate of hematologic relapse in Complete Response patients at 2 years by MRD status
Rate of hematologic relapse in Complete Response patients at 2 years by MRD status will be evaluated
Click on the lead sponsor to view all of their trials.